Hostname: page-component-848d4c4894-p2v8j Total loading time: 0.001 Render date: 2024-05-21T22:23:40.824Z Has data issue: false hasContentIssue false
  • English
  • Français

Cambio a monoterapia de amisulprida para la esquizofrenia resistente al tratamiento

Published online by Cambridge University Press:  12 May 2020

V. P. Kontaxakis ,
B. J. Havaky-Kontaxaki ,
P. P. Ferentinos ,
K. G. Paplos  and
C. R. Soldatos
V. P. Kontaxakis
Affiliation:
Departamento de Psiquiatría, Universidad de Atenas, Hospital Eginition, 74 Vas. Sophias Avenue, 11528Atenas, Grecia
B. J. Havaky-Kontaxaki
Affiliation:
Departamento de Psiquiatría, Universidad de Atenas, Hospital Eginition, 74 Vas. Sophias Avenue, 11528Atenas, Grecia
P. P. Ferentinos
Affiliation:
Departamento de Psiquiatría, Universidad de Atenas, Hospital Eginition, 74 Vas. Sophias Avenue, 11528Atenas, Grecia
K. G. Paplos
Affiliation:
Departamento de Psiquiatría, Universidad de Atenas, Hospital Eginition, 74 Vas. Sophias Avenue, 11528Atenas, Grecia
C. R. Soldatos
Affiliation:
Departamento de Psiquiatría, Universidad de Atenas, Hospital Eginition, 74 Vas. Sophias Avenue, 11528Atenas, Grecia
Get access

Resumen

El objetivo de este estudio fue evaluar el cambio a amisulprida (AMS) en la esquizofrenia resistente al tratamiento. Siete sujetos varones experimentaron un cambio a AMS y tuvieron seguimiento durante 8 semanas. Las puntuaciones de la PANSS mejoraron de 123 a 66 durante este periodo. Se concluyó que la AMS es interesante en el tratamiento de la esquizofrenia resistente al tratamiento.

Keywords

EsquizofreniaAntipsicóticosResistencia al tratamientoAmisulprida
Type
Comunicación breve
Information
European Psychiatry (Ed. Española) , Volume 14 , Issue 2 , March 2007 , pp. 95 - 98
Copyright
Copyright © European Psychiatric Association 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

[1]Agelink, MWKavuk, IAk, IClozapine with amisulpnde for refractory schizophrenia. Am J Psychiatry 2004;161:924-5.CrossRefGoogle ScholarPubMed
[2]American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: Ameritan Psychiatric Association; 1994.Google Scholar
[3]Buckley, PMiller, AOlsen, JGarver, DMiller, DDCsemansky, JWhen symptoms persisti clozapine angmentation strategies. Schizophr Bull 2001;27:615-28.CrossRefGoogle Scholar
[4]Citrome, LBilder, RMVolavka, JManaging treatment-resistant schizophrenia: evidence from randomized clinical triais. Journal of Psychiatric Practice 2002;8:205-15.CrossRefGoogle Scholar
[5]Croissant, BHermann, DOlbrich, RReduction of side effects by combining clozapine with amisulpride: case report and short review of clozapine-induced hypersalivation-a case report. Pharmacopsychiatry 2005;38:38-9.CrossRefGoogle ScholarPubMed
[6]Davis, JMChen, NGlick, IDA meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.CrossRefGoogle ScholarPubMed
[7]Guy, W editor. ECDEU assessment manual for psychopharmacology. Rockville: MD, US Department of Health, Education and Weltare; 1976.Google Scholar
[8]Kane, JHonigfeld, GSinger, JMeltzer, Hand the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.CrossRefGoogle Scholar
[9]Kay, SRFiszbein, AOpler, LAThe positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.CrossRefGoogle Scholar
[10]Kontaxakis, VPFerentinos, PPHavaki-Kontaxaki, BJPaplos, KGRoukas, DKChristodoulou, GNCase studies of adjunctive agents in clozapine-resistant schizophrenic patients. Clin Neuropharmacol 2005;28:50-3.CrossRefGoogle ScholarPubMed
[11]Lehman, AFLieberman, JADixon, LBMcGlashan, THMiller, ALPerkins, DO et al., American Psychiatric Association. Steemig Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, 2nd edition. Am J Psychiatry 2004;161(2 Suppl):1–56.Google Scholar
[12]Lerner, VBergman, JBorokhov, ALoewenthal, UMiodownik, CAugmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005;28:66–71.CrossRefGoogle ScholarPubMed
[13]Meltzer, HYBurnett, SBastani, BRamirez, LFEffects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-7.Google ScholarPubMed
[14]Miller, ALChiles, JAChiles, JKCrismon, MLRush, AJShon, SPThe Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999;60:649-57.CrossRefGoogle ScholarPubMed
[15]Moller, HJAmisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1101-11.CrossRefGoogle ScholarPubMed
[16]Mortimer, AMartin, SLoo, HPeuskens, JSOLIANOL Study Group. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004;19:63-9.CrossRefGoogle Scholar
[17]Mortimer, A.MHow do we choose between atypical antipsychotics? The advantages of amisulpride. Int. J. Neuropsychopharmacol. 2004;7(Suppl 1):S21-5.CrossRefGoogle ScholarPubMed
[18]Munro, JMatthiasson, POsbome, STravis, MPurcell, SCobb, AM et al. Amisulpride augmentation of clozapine: an upen non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004;110:292-8.CrossRefGoogle Scholar
[19]National Institute of Clinical Excellence. London: Health technology appraisal no. 43, NICE; 2002.Google Scholar
[20]Sechter, DPeuskens, JFleurot, ORein, WLecrubier, YAmisulpride Study Group. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002;27:1071-81.CrossRefGoogle Scholar
[21]Seeman, PAtypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27–38.CrossRefGoogle ScholarPubMed
[22]Zink, MHenn, FAThome, JCombination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004;19:56-8.CrossRefGoogle ScholarPubMed
[23]Zink, MKnopf, UHenn, FAThome, JCombination of clozapine and amisulpride in treatment-resistant schizophrenia—case reports and review of the literature. Pharmacopsychiatry 2004;37(1):26–31.Google ScholarPubMed